Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Yan, M; Ouyang, QC; Sun, T; Niu, LM; Yang, J; Li, L; Song, YH; Hao, CF; Chen, ZH; Orlandi, A; Ishii, N; Takabe, K; Franceschini, G; Ricci, F; Verschraegen, C; Liu, ZZ; Zhang, MW; Lv, HM; Liu, LP; Yang, XH; Xiao, HW; Gao, ZC; Li, XR; Dong, FY; Chen, XC; Qiao, JH; Zhang, GF

Yan, M (通讯作者)，Zhengzhou Univ, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou 450003, Peoples R China.;Yan, M (通讯作者)，Henan Canc Hosp, Zhengzhou 450003, Peoples R China.

LANCET ONCOLOGY, 2022; 23 (3): 353

Abstract

Background Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are sca......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索